Mitsubishi UFJ Trust & Banking Corp Sells 62,200 Shares of DaVita Inc. $DVA

Mitsubishi UFJ Trust & Banking Corp cut its holdings in DaVita Inc. (NYSE:DVA) by 52.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,973 shares of the company’s stock after selling 62,200 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in DaVita were worth $6,364,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of DVA. NewEdge Advisors LLC boosted its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the period. Goldman Sachs Group Inc. boosted its holdings in DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after buying an additional 28,739 shares during the period. Cerity Partners LLC boosted its holdings in DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock worth $376,000 after buying an additional 172 shares during the period. Bank of Nova Scotia boosted its position in shares of DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after acquiring an additional 176 shares during the period. Finally, Natixis boosted its position in shares of DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after acquiring an additional 3,264 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Trading Down 2.2%

Shares of DVA opened at $151.80 on Friday. The company has a market cap of $10.14 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 0.53 and a beta of 0.84. The stock has a 50-day moving average price of $151.18 and a 200-day moving average price of $131.48. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $159.42.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the company posted $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, analysts predict that DaVita Inc. will post 14.16 earnings per share for the current year.

Analysts Set New Price Targets

DVA has been the subject of a number of analyst reports. UBS Group raised their price objective on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. TD Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays raised their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 target price on DaVita in a research report on Thursday, February 5th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.